• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $JNCE

    Jounce Therapeutics Inc.

    Subscribe to $JNCE
    $JNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-4014, an anti-PD-1 antibody for combination therapy; JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: jouncetx.com

    Peers

    $ALRN
    $GTHX
    $MCRB
    $VKTX

    Recent Analyst Ratings for Jounce Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/11/2022$15.00 → $7.00Outperform → Neutral
    Robert W. Baird
    5/6/2022$15.00 → $20.00Outperform → Strong Buy
    Raymond James
    3/16/2022$17.00Outperform
    SMBC Nikko
    2/4/2022Market Perform → Outperform
    Cowen & Co.
    11/5/2021$10.00 → $15.00Outperform
    Raymond James
    9/14/2021$10.00Market Perform → Outperform
    Raymond James
    See more ratings

    Jounce Therapeutics Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Jounce Therapeutics Inc.

      15-12G - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/15/23 7:40:24 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:08 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Jounce Therapeutics Inc.

      25-NSE - Jounce Therapeutics, Inc. (0001640455) (Subject)

      5/4/23 8:40:09 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Jounce Therapeutics Inc.

      S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/4/23 7:30:46 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Jounce Therapeutics Inc.

      S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/4/23 7:30:23 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Jounce Therapeutics Inc.

      S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/4/23 7:29:58 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Jounce Therapeutics Inc.

      S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/4/23 7:29:32 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Jounce Therapeutics Inc.

      S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/4/23 7:29:06 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Jounce Therapeutics Inc.

      S-8 POS - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/4/23 7:28:42 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Jounce Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Concentra Biosciences, Llc

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:38:21 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tang Kevin C

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:37:26 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Concentra Biosciences, Llc claimed ownership of 36,367,727 shares

      3 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:35:30 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Salter-Cid Luisa

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/4/23 7:45:31 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Raythatha Jigar

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/4/23 7:45:13 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Murray Richard /Ca/

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/4/23 7:44:53 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Karsen Perry A

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/4/23 7:44:37 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kamen Robert

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/4/23 7:44:21 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Iannone Robert

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/4/23 7:43:59 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Duncan Barbara Gayle

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/4/23 7:43:41 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Jounce Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/14/24 8:50:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jounce Therapeutics Inc.

      SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/9/24 4:05:34 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/2/24 12:28:25 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      5/5/23 4:34:14 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jounce Therapeutics Inc.

      SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)

      4/12/23 4:15:15 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      4/7/23 4:00:15 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      3/28/23 4:00:18 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13D/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      3/17/23 4:00:13 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Jounce Therapeutics Inc.

      SC 13D - Jounce Therapeutics, Inc. (0001640455) (Subject)

      3/14/23 5:00:12 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/14/23 4:30:01 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Jounce Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more

    Jounce Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Jounce Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

      CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. "It's incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring over 20 years of biotechnology industry experience, but he also comes with a unique position as an early employee of the company at its inception," said Richard Murray, Ph.D., chief executive offic

      9/15/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer. "The addition of Dmitri to the Jounce team comes at an exciting juncture in our company development," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Dmitri brings a broad knowledge of contemporary immuno-oncology approaches, tumor immunology and cancer biology. His expertise with preclinical target discovery and first-in-human research will

      4/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors

      CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors. “We are thrilled to welcome Luisa to our board of directors,” said Perry Karsen, chairman of the board of Jounce Therapeutics. “Luisa brings over 20 years of experience in the healthcare industry, specifically in immunology and immuno-oncology, and we look forward to the unique and valuable perspective that her strategic leadership will bring to Jounce.” Dr. Salter-Cid currently serves a

      2/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Jounce Therapeutics from Outperform to Neutral and set a new price target of $7.00 from $15.00 previously

      5/11/22 6:18:27 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Jounce Therapeutics from Outperform to Strong Buy and set a new price target of $20.00 from $15.00 previously

      5/6/22 7:22:10 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SMBC Nikko initiated coverage on Jounce Therapeutics with a new price target

      SMBC Nikko initiated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $17.00

      3/16/22 7:50:25 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics upgraded by Cowen & Co.

      Cowen & Co. upgraded Jounce Therapeutics from Market Perform to Outperform

      2/4/22 5:57:02 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on Jounce Therapeutics with a new price target

      Raymond James reiterated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $15.00 from $10.00 previously

      11/5/21 6:48:49 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Jounce Therapeutics from Market Perform to Outperform and set a new price target of $10.00

      9/14/21 6:26:48 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Jounce Therapeutics with a new price target

      Piper Sandler initiated coverage of Jounce Therapeutics with a rating of Overweight and set a new price target of $20.00

      3/15/21 6:45:51 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird resumed coverage on Jounce Therapeutics

      Robert W. Baird resumed coverage of Jounce Therapeutics with a rating of Buy

      2/28/21 10:58:34 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright resumed coverage on Jounce Therapeutics with a new price target

      HC Wainwright resumed coverage of Jounce Therapeutics with a rating of Buy and set a new price target of $15.00 from $11.00 previously

      2/26/21 7:29:17 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redx and Jounce Announce Recommended Business Combination

      Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the

      2/23/23 2:30:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Reports Third Quarter 2022 Financial Results

      - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with $130.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quart

      11/10/22 7:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

      CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Me

      10/27/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Reports Second Quarter 2022 Financial Results

      - INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - - Patient enrollment complete in the randomized, Phase 2 SELECT trial of vopratelimab in combination with pimivalimab; Data to be reported by year end - - Submitted two abstracts on preclinical LILRB programs to SITC 2022 - - Ended the quarter with $162.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and developmen

      8/4/22 7:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022

      CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2022 financial results and provide a corporate update on Thursday, August 4, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Medi

      7/28/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Reports First Quarter 2022 Financial Results

      - Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 - - Target enrollment achieved in SELECT trial of vopratelimab in combination with pimivalimab; data expected in 2H2022 - - Ended the quarter with $186.4 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pr

      5/5/22 7:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022

      CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2022 financial results and provide a corporate update on Thursday, May 5, 2022. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 9072989. The live webcast can be accessed under "Events & Presentations" in the Investors an

      4/28/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022

      CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 8998936. The live webcast can be accessed under "E

      2/23/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021

      CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2021 financial results and provide a corporate update before market open on Thursday, November 4, 2021. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. E.T. Conference Call and WebcastTo access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 6873343. The live webcast can be accessed under "Events & Presenta

      10/28/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Jounce Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jounce Therapeutics Announces Closing of Tender Offer

      CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC ("Concentra"), through its wholly owned subsidiary Concentra Merger Sub, Inc. ("Concentra Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 per share in cash plus a non-tradeable contingent value right (a "CVR") per share. The $1.85 per share upfront consideration represents a premium of approximately

      5/3/23 8:35:17 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce's Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination"). Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Conc

      4/3/23 2:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfront con

      3/27/23 9:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

      CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review. The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors. JTX-8064, is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage rec

      3/16/23 4:30:00 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today confirmed that Concentra Biosciences, LLC ("Concentra"), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal ("the Proposal") to acquire

      3/14/23 9:00:00 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redx and Jounce Announce Recommended Business Combination

      Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the

      2/23/23 2:30:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Announces Restructuring

      CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent. The decision to reduce its workforce was made as Jounce believes advancement of its clinical programs, JTX-8064 and vopratelimab, requires funding and a scope that the Company cannot pursue on its own and will be seeking business development opportunities for both programs. "We believe data in both the SELECT and INNATE clinical trials is intriguing, but to date neither study has demonstrated clin

      2/22/23 5:00:00 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

      -- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020. As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement have also been terminated. Gilead will acquire certain related intellectual property, including all outstanding rights o

      12/27/22 4:30:00 PM ET
      $GILD
      $JNCE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

      FOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020.  As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement have also been terminated. Gilead will acquire certain related intellectual property, including all outstanding rights of Jounce to GS-1811, pursuant to the transaction agreement. GS-1811,

      12/27/22 4:30:00 PM ET
      $GILD
      $JNCE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

      - INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of prior treatment including a PD-1 inhibitor showed a durable partial response with combination treatment - - SELECT randomized Phase 2 trial data showed encouraging trends in the low dose vopratelimab (vopra) arm in combination with pimi compared to pimi alone - - Shorter duration of target engagement with vopra 0.03 mg/kg may avoid T cell exhaustion from agonist stimulation, leading to clinical benefit - CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jounce The

      12/8/22 7:50:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care